Accuray Reaches 100th U.S. CyberKnife System Installation
"Our installation of the 100th CyberKnife System within the United Statesshows the progress we're making in expanding patient access to the benefits ofradiosurgery," said Euan S. Thomson, Ph.D., president and CEO of Accuray. "Itis our continued goal to make radiosurgery an option that is available andaccessible to cancer patients around the world, and achievement of thisnational milestone means we're one step closer to that goal."
About the CyberKnife(R) Robotic Radiosurgery System
The CyberKnife Robotic Radiosurgery System is the world's only roboticradiosurgery system designed to treat tumors anywhere in the bodynon-invasively. Using continual image guidance technology and computercontrolled robotic mobility, the CyberKnife System automatically tracks,detects and corrects for tumor and patient movement in real-time throughoutthe treatment. This enables the CyberKnife System to deliver high-doseradiation with pinpoint precision, which minimizes damage to surroundinghealthy tissue and eliminates the need for invasive head or body stabilizationframes.
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is aglobal leader in the field of radiosurgery dedicated to providing an improvedquality of life and a non-surgical treatment option for those diagnosed withcancer. Accuray develops and markets the CyberKnife Robotic RadiosurgerySystem, which extends the benefits of radiosurgery to include extracranialtumors, including those in the spine, lung, prostate, liver and pancreas. Todate, the CyberKnife System has been used to treat more than 50,000 patientsworldwide and currently more than 150 systems have been installed in leadinghospitals in the Americas, Europe and Asia. For more information, please visithttp://www.accuray.com.
Safe Harbor Statement
The foregoing may contain certain forward-looking statements that involverisks and uncertainties, including uncertainties associated with the medicaldevice industry. Except for the historical information contained herein, thematters set forth in this press release, including statements relating toclinical studies, regulatory review and approval, and commercialization ofproducts are forward-looking statements within the meaning of the "safeharbor" provisions of the Private Securities Litigation Reform Act of 1995.Forward-looking statements speak only as of the date the statements are madeand are based on information available at the time those statements are madeand/or management's good faith belief as of that time with respect to futureevents. You should not put undue reliance on any forward-looking statements.Important factors that could cause actual performance and results to differmaterially from the forward-looking statements we make include: marketacceptance of products; competing products, the combination of our productswith complementary technology; and other risks detailed from time to timeunder the heading "Risk Factors" in our report on Form 10-K for the 2008fiscal year, as updated in our Form 10-Q filed on December 19, 2008 and ourother filings with the Securities and Exchange Commission. The Company'sactual results of operations may differ significantly from those contemplatedby such forward-looking statements as a result of these and other factors. Weassume no obligation to update forward-looking statements to reflect actualperformance or results, changes in assumptions or changes in other factorsaffecting forward-looking information, except to the extent required byapplicable securities laws.
SOURCE Accuray Incorporated
You May Also Like